BWX Technologies (BWXT) Q2 2026 earnings review
Massive Commercial Surge Masks Government Margin Pinch; Major Pivot on Medical
BWXT delivered a robust Q2, highlighted by a staggering 72% YoY revenue surge in its Commercial Operations and a guidance hike across all metrics. The core narrative is accelerating demand for nuclear components and services. However, a strategic shocker stole the spotlight: BWXT is divesting its high-growth Medical business to double down on nuclear defense and commercial power. Meanwhile, despite management praising 'strong execution,' the Government Operations segment saw a 5% drop in Adjusted EBITDA and shrinking margins. The nuclear macro tailwind is undeniably strong, but the company is shedding diversification to chase it.
🐂 Bull Case
Commercial revenue jumped 72% YoY to $302.5M, driving total company top-line beats. SMRs, CANDU life extensions, and recent acquisitions (Kinectrics, PCG) are translating into immediate, high-velocity growth.
Management raised FY26 Adjusted EBITDA guidance to $662M-$672M and Free Cash Flow to $345M-$360M. The prompt integration of the Precision Components Group (PCG) acquisition secures a localized U.S. manufacturing footprint for future commercial orders.
🐻 Bear Case
Despite a 2% revenue uptick, Government Operations Adjusted EBITDA fell 5% YoY to $126.5M. Lower positive contract adjustments and a less favorable mix are eroding profitability in the company's historically stable cash cow.
The abrupt divestiture of the Medical unit removes a segment that management previously touted as a double-digit growth engine, concentrating risk entirely on large-scale nuclear power and defense contracting cycles.
⚖️ Verdict: 🟢
Bullish. The strategic pivot to sell Medical and acquire PCG clarifies BWXT's identity as a pure-play nuclear component heavyweight. The nuclear renaissance is real, and BWXT's Commercial growth rate proves they are capturing the upside, overriding near-term Government margin noise.
Key Themes
Commercial Operations Leading the Charge
Commercial Operations is undeniably the star, delivering $302.5M in Q2 revenue (+72% YoY). This segment has radically transformed over the last year via organic wins in commercial nuclear components, field services, and the Kinectrics integration. Adjusted EBITDA for the segment more than doubled YoY to $36.1M (+123%). The segment is accelerating the total company's growth profile.
Abrupt Reversal: Divesting the Medical Business
For the past two years, management aggressively pitched the Medical segment as a 20% CAGR growth engine, spotlighting products like Tc-99 and TheraSphere. In Q2, they abruptly announced its sale to 'increase focus and resources' on core nuclear defense and commercial power. While this purifies the nuclear power thesis, it sacrifices revenue diversification and ditches a high-margin diagnostic isotope market that took years to build.
Government Operations Margin Compression
Management's press release cited 'strong execution across our business,' but the data in Government Operations contradicts this bullishness. Segment revenue grew 2%, but Adjusted EBITDA dropped 5% YoY from $133.0M to $126.5M. Margin decelerated from 22.6% a year ago to 21.0%. The stated culprits—lower positive contract adjustments (EACs) and 'less favorable mix'—suggest the onboarding of new defense fuels and HPDU contracts is dragging down legacy profitability exactly as feared in prior quarters.
U.S. Capacity Expansion: PCG Acquisition Closed
BWXT closed the Precision Components Group (PCG) acquisition on July 1, 2026. This is a critical strategic driver that immediately establishes a U.S. commercial nuclear component footprint. By securing N-stamp manufacturing capacity stateside, BWXT is positioning itself ahead of anticipated U.S. large-scale reactor and SMR orders, directly integrating this new capacity into their raised FY26 guidance.
Broad Macro Nuclear Renaissance
The macro backdrop remains BWXT's ultimate safety net. Management described demand for new nuclear solutions as 'remarkably deep and broad.' This validates their strategy of 'betting on the race, not the horse,' positioning the company to supply TRISO fuel, SMR components (like the BWRX-300), and large-scale reactor internals regardless of which specific OEM dominates the global energy transition.
Elevated Capital Intensity
To support its massive backlog and commercial scale-up, BWXT is burning significantly more cash on infrastructure. Capital Expenditures in Q2 jumped 27% YoY to $41.4M. Management has previously warned that CapEx could drift into the ~7% of sales territory to fund U.S. commercial expansion (Mount Vernon greenfield). This elevated spend will act as a near-term ceiling on Free Cash Flow conversion.
Broader Industry Execution Risk
BWXT is executing internally, but they remain tethered to the EPC (Engineering, Procurement, Construction) industry's ability to build reactors. If utility customers delay orders due to overarching cost overruns (e.g., Vogtle overhangs) or supply chain bottlenecks elsewhere, BWXT's aggressive capacity investments could sit idle.
Other KPIs
Stable and massive. Government Operations holds $6.80B, while Commercial Operations sits at $1.60B. This provides multi-year visibility and de-risks the capital investments currently being made.
Declined 9% YoY from $126.3M in 25Q2. While operating cash flow remained relatively flat at $156.4M, the aforementioned 27% jump in CapEx ($41.4M) ate into the free cash generation.
Corporate expenses expanded 14% YoY, an acceleration in overhead costs that management will need to monitor as they integrate PCG and stand up new U.S. manufacturing hubs.
Guidance
Accelerating. Raised from '>$3.75B'. Implies approximately 18.8% YoY growth compared to FY25's $3.19B. This guidance explicitly includes the newly acquired PCG business, meaning some of this raise is inorganic.
Accelerating. Raised from $650-$665M. At the midpoint ($667M), this represents a 16.1% YoY growth rate over FY25's $574M. Given the margin contraction in Gov Ops, this upgrade relies heavily on Comm Ops volume and PCG integration.
Accelerating. Raised from $4.60-$4.75. The $4.75 midpoint reflects an 18.5% jump from FY25's $4.01. Lower interest expense and a slightly higher tax rate are baked into this bottom-line trajectory.
Accelerating significantly. Raised aggressively from $315-$330M. This implies better-than-expected working capital dynamics in the back half of the year, despite rising CapEx demands.
Key Questions
Medical Unit Valuation and Dilution
You are divesting a unit that was previously touted as a 20% CAGR growth engine. What are the expected financial terms of the sale, and how much EBITDA is walking out the door? Will the proceeds be purely allocated to the U.S. commercial build-out?
PCG's Organic vs Inorganic Contribution
You've baked PCG into the upgraded FY26 guidance. Can you disaggregate how much of the $10M-$12M EBITDA guidance bump is driven by organic outperformance versus the inorganic addition of PCG for the second half of the year?
Government Operations Margin Headwinds
Government Operations margins compressed to 21.0% due to less favorable mix and lower EACs. With new defense fuels and HPDU contracts continuing to ramp up, should we expect this mix headwind to persist or accelerate into the back half of 2026?